Macrocyclics
Duke Halloran is an experienced professional in the fields of production management and chemistry. Currently serving as the Production Manager and Business Development Lead at Macrocyclics since October 2016, Duke manages a small manufacturing team, plans production operations, and supports various departments including purchasing and sales. Prior experience includes roles as a QC Lab Tech at Stratas Foods, where Duke performed quality testing and product approvals, and as a Fiber Lab Technician at Consumer Testing Laboratories, conducting mechanical and chemical analyses of textile fibers. Duke holds a Master of Science and a Master of Business Administration in Supply Chain Management from the Naveen Jindal School of Management at UT Dallas and a Bachelor of Arts in Chemistry from the University of Arkansas.
This person is not in any teams
This person is not in any offices
Macrocyclics
Macrocyclics, Inc., a manufacturer of customized chelating agents, is dedicated to leading-edge development of new chelation chemistry platforms critical for advancement of diagnostic and therapeutic medicine. We provide a broad library of catalog products designed to meet the needs of our basic and applied research customers as well as custom cGMP products and services to accelerate early stage clinical development programs. We also offer expert consulting services related to fundamental chelation chemistry and bioconjugation. Macrocyclics has a cutting-edge research and development strategy geared toward meeting the emerging needs of the medical community with both commercial and academic collaborations in mind. Our molecular imaging platform technology is adaptable to a broad range of radionuclides such as copper 64, gallium 68 and zirconium 89 for positron emission tomography (PET) and gadolinium and other lanthanide ions for optical and magnetic resonance imaging (MRI). Our products include an extensive line of bifunctional ligands designed specifically for bio-targeting in combination with monoclonal antibodies and peptide fragments. Since 1996, Macrocyclics has been the most trusted name in metal-ligand chelating technologies.